ATLANTA, Oct. 15 /PRNewswire-FirstCall/ -- Today, Formatech, Inc. announced that GeoVax Labs, Inc.'s (OTC Bulletin Board: GOVX) ("GeoVax") ("Company") HIV/AIDS vaccine will be the first clinical candidate that is formulated and filled under its Fillanthropy Program. The production run is scheduled to be completed in January 2010. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine for use in support of GeoVax's upcoming clinical trials.
"We're excited to have the opportunity to work with GeoVax on this program," said Jeffrey Bernard, Formatech's Director of Business Development. "The prevention, and eventual treatment, of HIV-1 certainly is a worthy cause. We're pleased to donate our services for this beneficial program and we wish GeoVax continued success with this promising vaccine."
"This generous gift represents a substantial cost savings to GeoVax and we graciously thank Formatech for helping the Company work towards our goal of managing and preventing the spread of HIV/AIDS through the development of a vaccine. The vials, which will contain our DNA vaccine, will be frozen and used with our future trials. This lot should allow us enough vaccine for upcoming preventative and therapeutic clinical trials," stated Robert McNally, Ph.D., President and Chief Executive Officer. "Additionally, as a thank you for this donation and in keeping with Formatech's philosophy behind their program, GeoVax will contribute a portion of this savings to a HIV/AIDS charity, to be named at a later date. Support for a vaccine within the HIV/AIDS community is strong, the need is vast and our commitment to developing a therapeutic and preventative vaccine is steadfast."
To obtain more information on participating in the Fillanthropy program, companies are encouraged to contact Jeffrey Bernard, Director of Business Development at Formatech (email@example.com).
About the Fillanthropy Program
Each month beginning in January 2010, Formatech will donate the services required to aseptically fill and finish one lot of drug product for selected therapeutic candidates that are entering human clinical trials. To be eligible, companies must be developing a clinical candidate that is delivered as a sterile injectable product. When selecting a candidate, Formatech considers both the product's potential therapeutic benefit and the financial need of the sponsor. To apply for participation in this program, companies are encouraged to contact Jeffrey Bernard at 978-725-9077 x 3164 or firstname.lastname@example.org.
Formatech, founded in 1993, is based in Andover, Massachusetts. The company provides contract services that deliver unique solutions to product development/manufacturing challenges, including preformulation/formulation development of all common dosage forms, such as lyophilized dosage forms, cell culture/fermentation process development and purification/downstream process optimization.
Their aseptic manufacturing facility produces liquid and lyophilized dosage units for clinical supplies or small-scale commercial products. Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and full ICH Guideline Stability Programs.
Formatech's mission is to "Help make new drugs happen at the speed of science."
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).
GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.
GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID a division of the NIH.
Safe Harbor Statement
All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.
SOURCE GeoVax Labs, Inc.
|SOURCE GeoVax Labs, Inc.|
Copyright©2009 PR Newswire.
All rights reserved